Abstract:
As a substitution for hormone replacement therapy, many breast cancer patients use black cohosh (BC) extracts in combination with doxorubicin (DOX)-based chemotherapy. In this study, we evaluated the viability and survival of BC- and DOX-treated MCF-7 cells. A preclinical model of MCF-7 xenografts was used to determine the influence of BC and DOX administration on tumor growth and metabolism. The number of apoptotic cells after incubation with both DOX and BC was significantly increased (~100%) compared to the control. Treatment with DOX altered the potential of MCF-7 cells to form colonies; however, coincubation with BC did not affect this process. In vivo, PET-CT imaging showed that combined treatment of DOX and BC induced a significant reduction in both metabolic activity (29%) and angiogenesis (32%). Both DOX and BC treatments inhibited tumor growth by 20% and 12%, respectively, and combined by 57%, vs. control. We successfully demonstrated that BC increases cytotoxic effects of DOX, resulting in a significant reduction in tumor size. Further studies regarding drug transport and tumor growth biomarkers are necessary to establish the underlying mechanism and potential clinical use of BC in breast cancer patients.
摘要:
作为激素替代疗法的替代品,许多乳腺癌患者使用黑升麻(BC)提取物联合多柔比星(DOX)化疗.在这项研究中,我们评估了BC和DOX处理的MCF-7细胞的活力和存活率。MCF-7异种移植物的临床前模型用于确定BC和DOX给药对肿瘤生长和代谢的影响。与对照相比,用DOX和BC孵育后的凋亡细胞的数量显著增加(〜100%)。用DOX处理改变了MCF-7细胞形成集落的潜力;然而,与BC共同孵育不会影响此过程。在体内,PET-CT成像显示DOX和BC的联合治疗引起代谢活性(29%)和血管生成(32%)的显著降低。DOX和BC治疗都抑制了20%和12%的肿瘤生长,分别,加起来是57%,vs.控制。我们成功地证明了BC增加了DOX的细胞毒性作用,导致肿瘤大小显著减小。关于药物转运和肿瘤生长生物标志物的进一步研究对于建立乳腺癌患者BC的潜在机制和潜在临床应用是必要的。